论文部分内容阅读
目的探讨顺铂联合培美曲塞一线治疗老年晚期肺腺癌的临床疗效与安全性。方法选取2012年8月至2013年8月间收治的80例老年晚期肺腺癌患者,采取随机数字表法分为对照组和观察组,每组40例。对照组患者给予顺铂联合吉西他滨治疗,观察组患者给予顺铂联合培美曲塞治疗,对比两组患者的近期疗效、不良反应及生存率。结果观察组患者的总有效率为70.0%,对照组为52.5%,差异有统计学意义(2=5.46,P<0.05)。观察组与对照组患者的胃肠道反应、白细胞降低及血小板降低的发生率差异有统计学意义(均P<0.05)。观察组与对照组患者静脉炎发生率差异无统计学意义(P>0.05)。观察组与对照组患者治疗3个月、6个月后的生存率差异无统计学意义(P>0.05)。观察组与对照组患者治疗12个月后的生存率差异有统计学意义(P<0.05)。结论顺铂联合培美曲塞治疗老年晚期肺腺癌的临床疗效显著,不良反应较少,安全性高,随访生存率较高,值得推广。
Objective To investigate the clinical efficacy and safety of cisplatin plus pemetrexed in the treatment of senile advanced lung adenocarcinoma. Methods Eighty elderly patients with advanced lung adenocarcinoma who were admitted between August 2012 and August 2013 were randomly divided into control group and observation group with 40 cases in each group. Patients in the control group were treated with cisplatin combined with gemcitabine. Patients in the observation group were treated with cisplatin combined with pemetrexed, and the short-term efficacy, adverse reactions and survival rate were compared between the two groups. Results The total effective rate in the observation group was 70.0% and in the control group was 52.5%, the difference was statistically significant (2 = 5.46, P <0.05). There were significant differences in the incidences of gastrointestinal reactions, leukopenia and thrombocytopenia between the observation group and the control group (all P <0.05). There was no significant difference in the incidence of phlebitis between observation group and control group (P> 0.05). There was no significant difference in the survival rate between the observation group and the control group after 3 months and 6 months (P> 0.05). The difference of survival rate between the observation group and the control group after 12 months of treatment was statistically significant (P <0.05). Conclusion Cisplatin combined with pemetrexed treatment of advanced lung adenocarcinoma of the elderly with significant clinical efficacy, fewer adverse reactions, high safety, high follow-up survival rate, it is worth promoting.